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Background:  Long-term follow-up of clinical trials with lipid-lowering medications has suggested a continuation of event reduction after study 
completion. We performed a meta-analysis to evaluate the persistence of the mortality benefit of lipid-lowering therapy after the end of clinical trials, 
when all patients were advised to take the same open-label lipid-lowering therapy.
Methods:  Searches of Medline, the Cochrane Library, Web of Science, and ClinicalTrials.gov were performed to identify randomized clinical trials 
of lipid-lowering agents with a second report describing results following the end of the trial. Odds ratios (ORs) for all-cause and for cardiovascular 
mortality were calculated separately for each study for the randomized phase and for the open-label phase and compared using random-effects 
meta-analysis.
Results:  The analysis included 8 clinical trials on 44255 patients and 8144 deaths. During the randomized phase, patients randomized to 
active medication were about six and a half times as likely to receive active therapy than those randomized to control. The ratio of the percentage 
of patients receiving active therapy among the group randomized to receive it to the percentage of those receiving active therapy among those 
randomized to placebo (AMR) was 6.52, IQR 4.88-10.11. During the open-label phase, patients initially randomized to control received active 
therapy in nearly identical proportions as those randomized to active therapy (AMR 1.02, IQR 0.92-1.14). All-cause and cardiovascular mortality 
were lower in the active intervention group during the randomized phase (OR 0.84, 95% CI 0.76-0.93; p=0.0006 and 0.72, 95% CI 0.63-0.82, 
p<0.0001, respectively). The lower mortality among those initially randomized to active therapy persisted during the open-label follow-up phase (OR 
0.90, 95% CI 0.84-0.97, p=0.0035 and 0.82 95% CI 0.73-0.93, p=0.0014), when patients in both randomized groups received active therapy in 
similar proportions.
Conclusions:  The decrease in mortality with lipid-lowering therapy in clinical trials persists after discontinuation of randomized therapy when 
patients in both the treatment and placebo groups receive active therapy.
